Anti-HIV-1 Antibodies: An Update.

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Wanwisa PromsoteAmarendra Pegu

Abstract

Even after more than 30 years since its discovery, there is no cure for HIV-1 infection. Combination antiretroviral therapy (cART) is currently the only HIV-1 infection management option in clinics. Despite its success in suppressing viral replication and converting HIV-1 from a lethal infection to a chronic and manageable disease, cART treatment is life long and long-term use can result in major drawbacks such as high cost, multiple side effects, and an increase in the development of multidrug-resistant escape mutants. Recently, antibody-based anti-HIV-1 treatment has emerged as a potential alternative therapeutic modality for HIV-1 treatment and cure strategies. These antibody-based anti-HIV-1 treatments comprising either receptor-targeting antibodies or broad neutralizing antibodies (bNAbs) are currently being developed and evaluated in clinical trials. These antibodies have demonstrated potent antiviral effects against multiple strains of HIV-1, and shown promise for prevention, maintenance, and prolonged remission of HIV-1 infection. This review gives an update on the current status of these antibody-based treatments for HIV-1, discusses their mechanism of action and the challenges in developing them, providing insight for...Continue Reading

References

Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·C Y WangC V Hanson
Nov 30, 1999·Nature·T W ChunA S Fauci
Jan 15, 2004·The Journal of Infectious Diseases·Daniel R KuritzkesWilliam R Shanahan
Nov 30, 2004·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Bruce J DezubeRobert A Mastico
Dec 23, 2008·Journal of Immunological Methods·Johannes F ScheidMichel C Nussenzweig
Jan 19, 2010·Nature Biotechnology·Jonathan ZalevskyJohn R Desjarlais
Apr 10, 2010·The Journal of Infectious Diseases·Jeffrey M JacobsonWilliam C Olson
May 5, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dirk PonselKathrin Tissot
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old
Jan 8, 2013·Current Opinion in Virology·Timothy J Henrich, Daniel R Kuritzkes
Sep 4, 2015·Clinical and Experimental Immunology·Julie E LedgerwoodUNKNOWN VRC 602 Study Team
Sep 29, 2015·The Journal of Clinical Investigation·Julia A M SungGuido Ferrari
Oct 21, 2015·Nature Communications·Amarendra PeguGary J Nabel
Dec 25, 2015·Science Translational Medicine·Rebecca M LynchUNKNOWN VRC 601 Study Team
Mar 20, 2016·British Journal of Anaesthesia·S HeschlM Rigaud
May 12, 2016·Annual Review of Immunology·Dennis R Burton, Lars Hangartner
Jun 18, 2016·Cell·Stylianos BournazosJeffrey V Ravetch
Jul 28, 2016·Science·David M MargolisBarton F Haynes
Dec 14, 2016·The New England Journal of Medicine·Katharine J BarTae-Wook Chun
Dec 14, 2016·The New England Journal of Medicine·Marina CaskeyMichel C Nussenzweig
Jan 17, 2017·Nature Medicine·Marina CaskeyFlorian Klein
Apr 20, 2017·Current Opinion in HIV and AIDS·Marie PanceraPeter D Kwong

❮ Previous
Next ❯

Citations

Jan 20, 2021·The Journal of Clinical Investigation·Adrienne E SwanstromGregory Q Del Prete
Jun 29, 2021·Expert Opinion on Emerging Drugs·Marco PiscagliaGiuliano Rizzardini

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00089700
NCT00784147
NCT02475629
NCT02369146
NCT01668043
NCT00642707
NCT02355184
NCT03721510

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.